GSA Capital Partners’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,071
Closed -$286K – 1850
2026
Q2
$286K Buy
+1,071
New +$250K 0.02% 1331
2025
Q1
– Sell
-1,717
Closed -$236K – 1637
2024
Q4
$236K Buy
+1,717
New +$226K 0.02% 1334
2024
Q2
– Sell
-6,564
Closed -$992K – 1613
2024
Q1
$992K Buy
+6,564
New +$937K 0.08% 443
2022
Q1
– Sell
-8,175
Closed -$1.1M – 1393
2021
Q4
$1.1M Buy
+8,175
New +$1.22M 0.14% 168
2020
Q4
– Sell
-2,676
Closed -$413K – 1195
2020
Q3
$413K Buy
+2,676
New +$385K 0.07% 511
2020
Q1
– Sell
-2,174
Closed -$302K – 1051
2019
Q4
$302K Buy
+2,174
New +$242K 0.04% 1018
2016
Q3
– Sell
-13,100
Closed -$174K – 1756
2016
Q2
$174K Sell
13,100
-5,600
-30% -$86.3K 0.01% 1609
2016
Q1
$347K Buy
+18,700
New +$332K 0.02% 1229

Other funds holding ASND

GSA Capital Partners's ASND Position: Q3 2026 in Review

GSA Capital Partners sold out of Ascendis Pharma (ASND) in Q3 2026, closing a stake of 1,071 shares — an estimated $286K sold.

GSA Capital Partners first reported a position in ASND in Q1 2016 and held it in 8 quarters. The position peaked at $1.1M in Q4 2021. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • GSA Capital Partners reported no remaining Ascendis Pharma position as of Q3 2026 after selling out during the quarter.
  • GSA Capital Partners sold 1,071 Ascendis Pharma shares in Q3 2026, an estimated $286K.
  • GSA Capital Partners first reported a position in Ascendis Pharma in Q1 2016 and held it in 8 quarters.
  • GSA Capital Partners's Ascendis Pharma position peaked at $1.1M in Q4 2021.
  • 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.